LNTH - Lantheus Non-GAAP EPS of $1.47 beats by $0.15 revenue of $319.9M beats by $5.48M
2023-11-02 07:09:05 ET
More on Lantheus
- Lantheus: Fast-Growing Radiotherapeutics Specialist Can Benefit From Lilly's POINT Biopharma Takeover
- Lantheus: Growth Well Priced In, Profitability Next Hurdle (Rating Downgrade)
- Lantheus: Not Quite Ready To Take The Plunge
- Lantheus Q3 2023 Earnings Preview
- Eli Lilly to acquire Point Biopharma in $1.4B deal (update)
For further details see:
Lantheus Non-GAAP EPS of $1.47 beats by $0.15, revenue of $319.9M beats by $5.48M